above and reasonably identify the record, specify the information being contested, and state the corrective action sought, with supporting information to show how the record is inaccurate, incomplete, untimely, or irrelevant.

RECORD SOURCE CATEGORIES:
Information is provided by HHS employees who apply for child care subsidies. Furnishing of the information is voluntary.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS OF THE ACT:
None.

Appendix A
1. For employees of the Office of the Secretary and the Administration on Aging, nationwide, contact: Child Care Subsidy Program Coordinator, PSC Work/Life Center, Room 1250, 330 C Street, SW, Washington, DC 20201.
2. For employees of the Substance Abuse and Mental Health Services Administration, contact: Director, Division of Human Resources Management, Office of Program Services, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, Maryland 20857.
3. For employees of the Food and Drug Administration, nationwide, contact: Child Care Subsidy Program Coordinator, Office of Human Resources and Management Services, Food and Drug Administration—HFA–410, 5600 Fishers Lane, Rockville, Maryland 20857.
4. For employees of the Program Support Center, contact: Work & Family Coordinator, Program Support Center, Room 1250, 330 C Street SW, Washington, DC 20201.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Notice of Meeting
In accordance with section 10(d) of the Federal Advisory Committee Act (5 U.S.C., Appendix 2), announcement is made of the Special Emphasis Panel meeting referenced below. A Special Emphasis Panel (SEP) is a committee of experts selected to conduct scientific reviews of grant applications submitted for agency funding that are related to their areas of expertise. The committee members are drawn from an agency list of experts and are designated to serve for particular individual meetings rather than for extended fixed terms of service.
Substantial segments of the upcoming SEP meeting listed below will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C., 552(b)(6). Grant applications are to be reviewed and discussed at this meeting. These discussions are likely to include personal information concerning individuals associated with the applications. This information is exempt from mandatory disclosure under the above-cited statutes.
1. Name of SEP: Health Research Dissemination & Implementation.
2. Date: March 5, 2001 (Open from 8 a.m. to 8:15 a.m. and closed for the remainder of the meeting).
3. Place: 6010 Building, 4th Floor, Conference Room D, Rockville, Maryland 20852.
4. Contact Person: Anyone wishing to obtain a roster of members or minutes of this meeting should contact Ms. Jenny Griffith, Committee Management Officer, Office of Research Review, Education and Policy, AHRQ, 2101 East Jefferson Street, Suite 400, Rockville, Maryland 20852, Telephone (301) 594–1847.
5. Agenda items for this meeting are subject to change as priorities dictate.
7. John M. Eisenberg, Director.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Advisory Committee on Childhood Lead Poisoning Prevention: Meeting
In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.
1. Name: Advisory Committee on Childhood Lead Poisoning Prevention.
2. Times and Dates: 8:30 a.m.—5:15 p.m., February 27, 2001; 8:30 a.m.—12:15 p.m., February 28, 2001.
3. Place: Swan Hotel Atlanta Hotel, 3391 Peachtree Road, N.E., Atlanta, Georgia 30326, telephone 404/365–0065.
4. Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 90 people.
5. Purpose: The Committee shall provide advice and guidance to the Secretary; the Assistant Secretary for Health; and the Director, CDC, regarding new scientific knowledge and technological developments and their practical implications for childhood lead poisoning prevention efforts. The Committee shall also review and report regularly on childhood lead poisoning prevention practices and recommend improvements in national childhood lead poisoning prevention efforts.
6. Matters to be Discussed: Agenda items include: Updates on Medicaid Targeted Screening issues, Case Management issues, EPA, and MMWR Publication Process, Treatment of Lead-Exposed Children Trial Presentation, and discussion of future topics.
7. Agenda items are subject to change as priorities dictate.
8. Opportunities will be provided during the meeting for oral comments. Depending on the time available and the number of requests, it may be necessary to limit the time of each presenter.
9. This notice is published less than 15 days prior to the meeting due to administrative delays.
10. Contact Person for More Information: Becky Wright, Program Analyst, Lead Poisoning Prevention Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 1600 Clifton Road, NE, M/S E–25, Atlanta, Georgia 30333, telephone 404/639–1789, fax 404/639–2570.
11. The Director, Management Analysis and Services Office has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Vaccines and Related Biological Products Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Vaccines and Related Biological Products Advisory Committee.
General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues.
Date and Time: The meeting will be held on March 7, 2001, from 8 a.m. to 6:30 p.m., March 8, 2001, from 8 a.m. to 6:30 p.m., and March 9, 2001, from 8 a.m. to 12:30 p.m.
Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.
Contact: Nancy T. Cherry or Denise H. Royster, Center for Biologics Evaluation and Research (HFM 71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, or FDA Advisory...